Sapna R. Srivastava

Sapna R.
Srivastava currently serves as Independent Director at SQZ Biotechnologies Co. since 2020, Independent Non-Executive Director at Aura Biosciences, Inc. since 2021, Director at AsclepiX Therapeutics LLC since 2019, Independent Director at Nuvalent, Inc. since 2021, Independent Director at Alumis, Inc. since 2022, Director at Trickle Up Program, Inc. since 2013, and Strategic Advisor at BioPlus Acquisition Corp.
Former roles include Independent Director at MYOS RENS Technology, Inc. from 2014 to 2016, Director at VelosBio, Inc. in 2020, Independent Director at Innoviva, Inc. from 2023 to 2025, Independent Director at Social Capital Suvretta Holdings Corp.
II from 2021 to 2023, Independent Director at Talaris Therapeutics, Inc. from 2021 to 2023, Independent Director at Tourmaline Bio, Inc. from 2023 to 2025, Chief Financial & Strategy Officer at Abide Therapeutics, Inc. from 2017 to 2019, Research Analyst at Morgan Stanley & Co. LLC, Analyst at Goldman Sachs & Co. LLC in 2010, Analyst at Thomas Weisel Partners LLC in 2010, Chief Financial & Strategy Officer at Intellia Therapeutics, Inc. from 2015 to 2016, Chief Financial Officer at eGenesis, Inc. in 2021, and Associate at JP Morgan Direct Corporate Finance.
Education includes a doctorate from New York University School of Medicine and an undergraduate degree from St. Xavier's College (Mumbai).